Indication
Hematologic Disorders
27 clinical trials
29 products
2 drugs
Clinical trial
A Phase 1 Study of ANV419 as Monotherapy, and ANV419 in Combination With Daratumumab or With Lenalidomide Plus Low-Dose Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma (OMNIA-2)Status: Terminated, Estimated PCD: 2023-07-12
Product
LenalidomideClinical trial
A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated With Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)Status: , Estimated PCD: 2039-09-01
Product
CTX001Product
ANV419Product
DaratumumabClinical trial
A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell DiseaseStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1/2/3 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) in Subjects With Transfusion-Dependent β-ThalassemiaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Product
SPK-8016Clinical trial
Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII InhibitorsStatus: Completed, Estimated PCD: 2020-10-14
Product
BD211Clinical trial
A Phase 1 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+Stem Cells Transduced With a Lentiviral Vector Encoding βA-T87Q-GlobinStatus: Recruiting, Estimated PCD: 2025-02-23
Product
OriCAR-017Clinical trial
A Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Anti-GPRC5D CAR-T Cell Product (OriCAR-017) in Subjects With Relapsed/Refractory Multiple Myeloma.Status: Recruiting, Estimated PCD: 2026-12-12
Product
HMPL-523Clinical trial
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune ThrombocytopeniaStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
A Phase I Multi-dose Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) With or Without Recombinant Human Interleukin-2 (rhIL-2) in Adults With Primary or Secondary Acute Myeloid Leukemia (AML) in Morphologic Complete Remission With Minimal Residual Disease (MRD) or Relapsed/Refractory (R/R) AMLStatus: Recruiting, Estimated PCD: 2024-06-03
Clinical trial
A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-ThalassemiaStatus: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239DStatus: Recruiting, Estimated PCD: 2025-03-11
Clinical trial
An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell TransplantationStatus: Withdrawn, Estimated PCD: 2026-03-01
Product
PUL-042Product
CYNK-001Product
GSK4172239DClinical trial
A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three CohortsStatus: Completed, Estimated PCD: 2019-08-01
Clinical trial
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.Status: Active (not recruiting), Estimated PCD: 2023-01-31
Product
ThrombosomesClinical trial
A Multi-Center, Observational Study in Males With Hemophilia AStatus: Completed, Estimated PCD: 2023-05-02
Clinical trial
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular ResponseStatus: Active (not recruiting), Estimated PCD: 2021-11-08
Product
AsciminibProduct
ImatinibProduct
NilotinibClinical trial
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)Status: Recruiting, Estimated PCD: 2024-06-01
Product
BusulfanProduct
FludarabineProduct
Stem cell transplantProduct
KeppraClinical trial
Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Related or Unrelated Donor After TCR αβ+T Cells/CD19+ B Cell Depletion in Children and Young Adults Affected by Malignant or Non-Malignant Hematological DisordersStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow TransplantationStatus: Recruiting, Estimated PCD: 2025-06-30
Product
VorinostatProduct
TacrolimusProduct
MethotrexateProduct
Mycophenolate MofetilDrug
cyclophosphamideClinical trial
Clinical Study on the Impact of Covid-19 Vaccine on Safety and Efficacy of Hematological Patients Received Allogeneic Hematopoietic Sem Cell TransplantationStatus: Withdrawn, Estimated PCD: 2023-11-01
Product
COVID-19 vaccineClinical trial
A Study on the Efficacy, Safety and Cellular Pharmacokinetics of RD13-02 Cell Injection in Patients With Relapsed or Refractory CD7-positive Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2025-02-20
Product
RD13-02Clinical trial
Clinical Study on Efficacy, Safety and Pharmacokinetics of CAR T Cell Injection in Patients With Recurrent or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-03-08
Clinical trial
Effect of Dose Fractionation of Testosterone Cypionate on Hematocrit in Transgender Men With Erythrocytosis Secondary to Testosterone Use.Status: Recruiting, Estimated PCD: 2025-01-31
Product
Testosterone CypionateClinical trial
Efficacy, Safety and Cytopharmacokinetics of RD13-02 Cell Injection in the Treatment of Patients With Recurrent or Refractory CD7-positive Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
A Study to Evaluate the Efficacy and Safety of CD7CAR-T Bridging to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed CD7 Positive Malignant Hematologic DiseasesStatus: Recruiting, Estimated PCD: 2025-04-25
Product
CD7 CAR-T cellsClinical trial
A Study for Safety, Efficacy and Cellular Pharmacokinetics of CD7 CAR-T Cell for Patients With Relapsed or Refractory CD7 Positive T-cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaStatus: Recruiting, Estimated PCD: 2024-03-20
Clinical trial
Prospective Observational Study on the Clinical Efficacy of Teclistamab in Patients With Relapsed and Refractory Multiple Myeloma in BelgiumStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Drug
Teclistamab